» Articles » PMID: 32230855

Cancer Cachexia and Related Metabolic Dysfunction

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2020 Apr 2
PMID 32230855
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer cachexia is a complex multifactorial syndrome marked by a continuous depletion of skeletal muscle mass associated, in some cases, with a reduction in fat mass. It is irreversible by nutritional support alone and affects up to 74% of patients with cancer-dependent on the underlying type of cancer-and is associated with physical function impairment, reduced response to cancer-related therapy, and higher mortality. Organs, like muscle, adipose tissue, and liver, play an important role in the progression of cancer cachexia by exacerbating the pro- and anti-inflammatory response initially activated by the tumor and the immune system of the host. Moreover, this metabolic dysfunction is produced by alterations in glucose, lipids, and protein metabolism that, when maintained chronically, may lead to the loss of skeletal muscle and adipose tissue. Although a couple of drugs have yielded positive results in increasing lean body mass with limited impact on physical function, a single therapy has not lead to effective treatment of this condition. Therefore, a multimodal intervention, including pharmacological agents, nutritional support, and physical exercise, may be a reasonable approach for future studies to better understand and prevent the wasting of body compartments in patients with cancer cachexia.

Citing Articles

Muscle loss in cancer cachexia: what is the basis for nutritional support?.

Faiad J, Andrade M, de Castro G, de Resende J, Coelho M, Aquino G Front Pharmacol. 2025; 16:1519278.

PMID: 40078277 PMC: 11897308. DOI: 10.3389/fphar.2025.1519278.


Imaging-based evaluation of cervical muscle mass and 6-month survival in males with hypopharyngeal carcinoma.

Lauren J, Keski-Santti H, Makitie A, Arponen O Acta Oncol. 2024; 63:950-957.

PMID: 39688227 PMC: 11681277. DOI: 10.2340/1651-226X.2024.40481.


Metabolic, Inflammatory, and Molecular Impact of Cancer Cachexia on the Liver.

Goncalves D, Gomes S, Seelaender M Int J Mol Sci. 2024; 25(22).

PMID: 39596015 PMC: 11593664. DOI: 10.3390/ijms252211945.


The application of QCT in the prognostic assessment of mCRC undergoing first-line treatment based on bevacizumab.

Liu X, Wu S, Dang W, Shen H, Sun M, Chen Y Future Oncol. 2024; 20(40):3433-3442.

PMID: 39558658 PMC: 11776858. DOI: 10.1080/14796694.2024.2430160.


Bidirectional association between perioperative skeletal muscle and subcutaneous fat in colorectal cancer patients and their prognostic significance.

Yan G, Liu L, Liu M, Jiang X, Chen P, Li M Front Nutr. 2024; 11:1381995.

PMID: 39360277 PMC: 11445023. DOI: 10.3389/fnut.2024.1381995.


References
1.
Vander Heiden M, Cantley L, Thompson C . Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324(5930):1029-33. PMC: 2849637. DOI: 10.1126/science.1160809. View

2.
Trobec K, von Haehling S, Anker S, Lainscak M . Growth hormone, insulin-like growth factor 1, and insulin signaling-a pharmacological target in body wasting and cachexia. J Cachexia Sarcopenia Muscle. 2011; 2(4):191-200. PMC: 3222822. DOI: 10.1007/s13539-011-0043-5. View

3.
Molinari F, Pin F, Gorini S, Chiandotto S, Pontecorvo L, Penna F . The mitochondrial metabolic reprogramming agent trimetazidine as an 'exercise mimetic' in cachectic C26-bearing mice. J Cachexia Sarcopenia Muscle. 2017; 8(6):954-973. PMC: 5700442. DOI: 10.1002/jcsm.12226. View

4.
Hojman P . Exercise protects from cancer through regulation of immune function and inflammation. Biochem Soc Trans. 2017; 45(4):905-11. DOI: 10.1042/BST20160466. View

5.
Farkas J, von Haehling S, Kalantar-Zadeh K, Morley J, Anker S, Lainscak M . Cachexia as a major public health problem: frequent, costly, and deadly. J Cachexia Sarcopenia Muscle. 2013; 4(3):173-8. PMC: 3774921. DOI: 10.1007/s13539-013-0105-y. View